Full Text View
Tabular View
No Study Results Posted
Related Studies
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
This study is currently recruiting participants.
Verified February 2011 by University of Pittsburgh

First Received on April 17, 2007.   Last Updated on February 17, 2011   History of Changes
Sponsor: University of Pittsburgh
Information provided by: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00462579
  Purpose

It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.


Condition
Acinetobacter Infections

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk Factors for Carbapenem-resistant Acinetobacter Baumannii

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 100
Study Start Date: April 2007
Estimated Study Completion Date: December 2013
Detailed Description:

The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.he following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

carbapenem-resistant acinetobacter baumannii positive cultures

Criteria

Inclusion Criteria:

  • Positive cultures of carbapenem-resistant acinetobacter baumannii

Exclusion Criteria:

  • Not meeting inclusion criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00462579

Contacts
Contact: David L Paterson, MD 412-648-6401 patersond@dom.pitt.edu
Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu

Locations
United States, Pennsylvania
UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: David L Paterson, MD     412-648-6401     patersond@dom.pitt.edu    
Contact: Diana Lynn Pakstis, RN, BSN     412-648-6553     pakstisdl@dom.pitt.edu    
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: David L Paterson, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: David Paterson, MD, UPMC
ClinicalTrials.gov Identifier: NCT00462579     History of Changes
Other Study ID Numbers: PRO07040057
Study First Received: April 17, 2007
Last Updated: February 17, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
carbapenem-resistant acinetobacter baumannii
positive culture
positive culture for carbapenem-resistant acinetobacter

Additional relevant MeSH terms:
Acinetobacter Infections
Moraxellaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on February 09, 2012